Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Fineline Cube Apr 4, 2026
Company Deals

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

Fineline Cube Apr 3, 2026
Company Deals Digital

Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform

Fineline Cube Apr 3, 2026
Company Deals

Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform

Fineline Cube Apr 3, 2026
Company Deals

Biocytogen and Sihuan Pharma Forge Strategic Partnership to Accelerate Innovative Drug Development Including Weight Management Therapies

Fineline Cube Apr 2, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Fineline Cube Apr 4, 2026
Company Drug

Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen

Fineline Cube Apr 4, 2026
Company

Boehringer Ingelheim Biopharmaceuticals (China) Completes PMDA GMP Inspection for Japan Market Supply

Fineline Cube Apr 28, 2025

German pharmaceutical leader Boehringer Ingelheim (BI) announced that its Shanghai-based subsidiary, Boehringer Ingelheim Biopharmaceuticals (China)...

Company Drug

CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors

Fineline Cube Apr 28, 2025

Zhejiang-based Zhejiang Shimai Pharmaceutical Co.,Ltd (CentryMed)’s CMDE005, an anti-EGFR×CD3 enzyme-controlled bispecific antibody (BsAb) developed using...

Company Drug

Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy

Fineline Cube Apr 28, 2025

US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval...

Company Drug

Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors

Fineline Cube Apr 28, 2025

China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...

Company Medical Device

Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China

Fineline Cube Apr 28, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the first prescription of AcornMed utLIFE-UC,...

Company Medical Device

Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler

Fineline Cube Apr 28, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has secured marketing approval...

Others

Roche’s Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics

Fineline Cube Apr 28, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported Q1 2025 financials with global group...

Company

BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline

Fineline Cube Apr 28, 2025

US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...

Company

Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China

Fineline Cube Apr 27, 2025

Global pharmaceutical company Merck (NYSE: MRK) released its Q1 2025 financial results, showing total sales...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors

Fineline Cube Apr 27, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received regulatory clearance...

Company Drug

InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for First-line CLL/SLL Treatment

Fineline Cube Apr 27, 2025

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has obtained regulatory approval from...

Company Deals

Chipscreen Biosciences Cuts Private Placement Proceeds to RMB 950 Million

Fineline Cube Apr 27, 2025

Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has revised its private placement proceeds to RMB...

Company Drug

Shanghai Junshi Biosciences’ Loqtorzi Receives NMPA Approval for Melanoma Treatment

Fineline Cube Apr 27, 2025

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received another...

Company Drug

Innovent Biologics’ Aoyixin Wins NMPA Approval for First-line NSCLC Treatment

Fineline Cube Apr 27, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another indication approval from...

Company Drug

CSPC Pharmaceutical Group Gains NMPA Approval for SYH2068 siRNA Clinical Trials

Fineline Cube Apr 27, 2025

China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has obtained approval from China’s National Medical Products...

Company Deals

Grand Pharma Group and Sirtex Medical US Launch Commercial Partnership in Medical Innovation

Fineline Cube Apr 27, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its subsidiary Chengdu Shetai Medical...

Company Deals Drug

Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)

Fineline Cube Apr 27, 2025

China-based Shanghai Henlius Biotech Inc., (HKG: 2696) has entered into a licensing agreement with South...

Policy / Regulatory

Digital-Intelligent Transformation of China’s Pharmaceutical Industry: 2025-2030 Plan Unveiled

Fineline Cube Apr 27, 2025

China’s Ministry of Industry and Information Technology, Ministry of Commerce, National Health Commission (NHC), and...

Company Deals

Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development

Fineline Cube Apr 27, 2025

China-based Zhejiang Jolly Pharmaceutical Co., Ltd. (SHE: 300181) announced an investment of RMB 20 million...

Company Drug

Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication

Fineline Cube Apr 27, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received another indication...

Posts pagination

1 … 150 151 152 … 646

Recent updates

  • Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline
  • Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
  • Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline
  • Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen
  • Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Others

Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline

Company Drug

Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.